CRISPR

CRISPR2-pgrmc1

ID

ZDB-CRISPR-190206-2

Name

CRISPR2-pgrmc1

Previous Names

None

Target

pgrmc1 (1)

Sequence

5' - GGAGACAAGCCTGCAGACTA - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
ecu4	pgrmc1

Expression

Gene expression in Wild Types + CRISPR2-pgrmc1

No data available

Phenotype

Phenotype resulting from CRISPR2-pgrmc1

No data available

Phenotype of all Fish created by or utilizing CRISPR2-pgrmc1

Phenotype	Fish	Conditions	Figures
ovarian follicle stage IV paqr7b expression decreased amount, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 6 from Wu et al., 2018
ovarian follicle stage III decreased amount, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 4 from Wu et al., 2018
whole organism decreased female fertility, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 5 from Wu et al., 2018
ovarian follicle stage IV increased amount, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 5 from Wu et al., 2018
oocyte stage IV adamts9 expression decreased amount, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 4 from Wu et al., 2019
oocyte maturation disrupted, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 5 from Wu et al., 2018
oocyte stage V decreased amount, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 5 from Wu et al., 2018
ovarian follicle stage IV decreased amount, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 4 from Wu et al., 2018
oocyte stage III pgr expression decreased amount, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 3 from Wu et al., 2019
oocyte stage IV mmp9 expression decreased amount, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 4 from Wu et al., 2019
ovarian follicle stage II decreased amount, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 4 from Wu et al., 2018
ovulation from ovarian follicle decreased occurrence, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 5 from Wu et al., 2018
oogenesis process quality, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 5 from Wu et al., 2018
ovarian follicle stage IV cellular response to progesterone stimulus process quality, abnormal	pgrmc1^ecu4/ecu4	chemical treatment by environment: (20R)-17,20-dihydroxypregn-4-en-3-one	Fig. 6 from Wu et al., 2018
ovarian follicle stage I increased amount, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 4 from Wu et al., 2018
ovary nuclear progesterone receptor binding process quality, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 6 from Wu et al., 2018
female mating behavior process quality, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 4 from Wu et al., 2018
yolk increased size, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 5 from Wu et al., 2018
oocyte stage IV pgr expression decreased amount, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 3 from Wu et al., 2019
ovarian follicle stage IV paqr7b expression increased amount, abnormal	pgrmc1^ecu4/ecu4	standard conditions	Fig. 6 from Wu et al., 2018
oocyte stage III pgr expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
female organism decreased fecundity, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 1 from Wu et al., 2019
oocyte stage IV adamts8a expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
ovary oocyte stage IV increased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 2 from Wu et al., 2019
oocyte stage IV mmp9 expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
female organism decreased fertility, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 1 from Wu et al., 2019
ovulation decreased occurrence, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 2 from Wu et al., 2019
oocyte stage IV adamts9 expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
oocyte maturation process quality, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 2 from Wu et al., 2019
oocyte stage IV adamts1 expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
oocyte stage IV pgr expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 3 from Wu et al., 2019
oocyte stage IV mmp2 expression decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 4 from Wu et al., 2019
ovary oocyte stage V decreased amount, abnormal	pgrmc1^ecu4/ecu4; pgrmc2^ecu10/ecu10	standard conditions	Fig. 2 from Wu et al., 2019

Citations